Home > PJ (current issue) > Letters | Search

PJ Online homeThe Pharmaceutical Journal
Vol 279 No 7463 p126
4 August 2007

This article
Reprint   Photocopy

PDF 40K, Acrobat Reader

Letters

• Retention fees
• White Paper (3)
• Athena
• The Journal


Letters to the Editor

Athena

Challenging statement regarding mosquitoes

From Mr J. A. Parry, MRPharmS

Your columnist, Athena, has made the most incredibly challenging statement (PJ, 21 July, p78) asserting that the mosquito Culex pipiensis the most common transmitter of malaria”. It is, to my mind, essential that this serious allegation should be repudiated immediately. If it were true, then malaria would be endemic throughout the UK, because Culex pipiens is overall the most abundant mosquito of our land, being overtaken only by Aedes cantans and Aedes rustica in some wooded areas.

Malaria is caused by species of the protozoon genus Plasmodium, of which there are many species. These parasites each have two hosts, one of which is a bloodsucking insect and the other a vertebrate, such as an anthropoid, bird, lizard or other. In anthropoid (ie, human, simian) malaria the parasite is carried only by one or more of the many species of anopheles mosquito. The parasite is passed between the two hosts alternately.

Anopheles mosquitoes may be recognised by their characteristic resting position in which the body, wings and proboscis are aligned in a forward-sloping position as opposed to the horizontal stance of culicines. The only British species, Anopheles maculipennis, does occur commonly in this country, most frequently in salt marshes, where in earlier times sporadic outbreaks of malaria (then known as “ague”) did occur. The wings of A maculipennis are dark-spotted, the only other indigenous mosquito that has spotted wings being Theobaldia annulata (and sometimes in the Scottish Highlands T alaskaensis). Both these are much larger.

Culex species, including Culex pipiens, have never been implicated in the transmission of anthropoid malaria. A telephone call to the London School of Hygiene and Tropical Medicine will confirm this.

This mistake would not in itself appear to be important, but journalists from the tabloids do peruse professional journals for juicy titbits and if the statement should be taken seriously, every open stretch of water from garden water butts to Windermere might be covered by a thin film of liquid paraffin or engine oil in order to kill all mosquito larvae and eradicate this “pest”. This of course has happened in areas of Africa such as Gambia (where the worst form of malaria, quaternary malaria, caused by Plasmodium falciparum is endemic), with catastrophic consequences for the local aquatic wildlife. It is important, therefore, that the statement is refuted at once.

There is a form of malaria called avian malaria, also caused by a plasmodium, which is indeed carried by culicine mosquitoes. It does not appear to be endemic in the UK, but it could explain how this misunderstanding may have occurred.

I am much surprised that this error was not noticed by The Journal‘s editorial team, or by any other pharmacist on the staff, because I should have thought that by now all pharmacists would have become aware of the causal organisms and vectors of malaria.

John Parry
Tenterden, Kent

 

ATHENA responds:

Ronald Ross won a Nobel Prize (1902) for demonstrating the existence of plasmodium in the wall of the midgut and salivary glands of a culex or common house mosquito (1898). Indeed the life cycle of the plasmodium was researched extensively in this species.

However since then, research has shown that the anopheles mosquito is the most common transmitter of malaria in humans. It has been suggested that the increasing numbers of culex in the domestic environment could lead to an increase in feeding on humans (as adverse to birds, their preferred targets) and transmission of disease. Culex is also a transmitter of West Nile virus, filariasis and Japanese encephalitis.

I offer my apologies for the wording in the article, which may have misled readers.

Send your letter to The Editor

Previous Topic (White Paper)
Next Topic (The Journal)

Back to Top


©The Pharmaceutical Journal